Q3 2017 Earnings Estimate for Sarepta Therapeutics, Inc. Issued By Oppenheimer Holdings (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Oppenheimer Holdings lowered their Q3 2017 EPS estimates for Sarepta Therapeutics in a note issued to investors on Thursday. Oppenheimer Holdings analyst H. Singh now anticipates that the biotechnology company will post earnings per share of ($0.78) for the quarter, down from their prior estimate of ($0.55). Oppenheimer Holdings currently has a “Buy” rating and a $76.00 target price on the stock. Oppenheimer Holdings also issued estimates for Sarepta Therapeutics’ Q4 2017 earnings at ($0.90) EPS, FY2018 earnings at ($2.25) EPS, FY2019 earnings at ($1.67) EPS and FY2020 earnings at $0.97 EPS.
Several other equities research analysts have also issued reports on the company. SunTrust Banks, Inc. upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the company from $30.00 to $30.97 in a report on Wednesday, April 5th. Vetr lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 price target for the company. in a report on Monday, May 22nd. Cowen and Company reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, April 28th. Robert W. Baird reiterated an “outperform” rating and set a $102.00 price target on shares of Sarepta Therapeutics in a report on Sunday, April 23rd. Finally, Nomura restated a “buy” rating and issued a $84.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, May 23rd. Eight analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $61.28.
Sarepta Therapeutics (SRPT) opened at 43.95 on Monday. Sarepta Therapeutics has a 12-month low of $22.61 and a 12-month high of $63.73. The company has a 50-day moving average of $34.41 and a 200 day moving average of $32.31. The stock’s market cap is $2.42 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter in the previous year, the business posted ($1.19) EPS. The company’s quarterly revenue was up 350000.0% on a year-over-year basis.
Several hedge funds have recently added to or reduced their stakes in SRPT. Prentiss Smith & Co. Inc. boosted its stake in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after buying an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Sarepta Therapeutics during the first quarter worth about $127,000. PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after buying an additional 2,800 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Sarepta Therapeutics during the first quarter worth about $209,000. Finally, Baird Financial Group Inc. purchased a new stake in Sarepta Therapeutics during the first quarter worth about $223,000. Institutional investors and hedge funds own 73.09% of the company’s stock.
In other news, SVP Shamim Ruff sold 12,138 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86. Following the sale, the senior vice president now directly owns 27,312 shares in the company, valued at $1,173,596.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sandesh Mahatme sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00. Following the sale, the chief financial officer now owns 41,736 shares in the company, valued at $1,711,176. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is currently owned by company insiders.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.